Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.
• Males or females aged 18 to 70 years of age.
• Participants who have a diagnosis of SLE confirmed by a rheumatologist.
• ANA-positive per the Central Lab at screening:
• (a) ANA (b) Anti-dsDNA (c) Anti-Smith (anti-Sm)
• Must be on the standard therapy regimen: antimalarials with or without OCSs
• Must have at screening and baseline:
∙ Clinical SLEDAI-2K ≥ 4 points OR
‣ Clinical SLEDAI-2K \< 4 with GC dose ≥ 7.5 mg/day (prednisone equivalent)
• Should have no evidence of current active infection, (e.g., pneumonia, tuberculosis \[TB\]) or previous TB
• Should have no evidence of malignancy; and clinically significant abnormalities (unless due to SLE).
• No medical history or signs or symptoms of active TB prior to or during Screening.
• Body weight ≥ 40.0 kg
⁃ Negative pregnancy test for females during screening
⁃ Normal HPV test result within 2 years prior to Week 0 (Day 1).
⁃ Willing and able to participate in all required study evaluations and procedures including completion of PROs.
⁃ Willing to not use any other forms of experimental treatment during the study.